中文名稱(chēng):丹參酮IIA | 英文名稱(chēng):Tanshinone IIA |
CAS:568-72-9 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | Shipping with blue ice. |
純度規(guī)格: 99.54% | 產(chǎn)品類(lèi)別: 抑制劑 |
貨號(hào): T2906 |
名稱(chēng) | Tanshinone IIA |
描述 | Tanshinone IIA (Tanshinone B) is a diterpene quinone natural product that targets the protein kinase domain of VEGF/VEGFR2. Tanshinone IIA inhibits angiogenesis and exhibits anti-inflammatory, antioxidant, and therapeutic activities against coronary heart disease. |
細(xì)胞實(shí)驗(yàn) | Tanshinone IIA (Tan IIA) is dissolved in DMSO (10 mM) and stored (in dark and -20°C), and serially diluted in a RPMI 1640 medium immediately prior to experiments[1]. A549 cells are counted in logarithmic phase and 6000 cells (90 μL volume) are placed in 96-well plates. 10 μL varying concentrations of Tanshinone IIA (final concentrations 80, 60, 40, 30, 20, 15, 10, 5 and 2.5 μM) and ADM (final concentrations 8, 4, 2, 1, 0.5 and 0.25 μM) are added into drug groups, while negative control group (vehicle group) is only added 10 μL DMSO or normal saline without Tanshinone IIA or ADM. Cells are incubated for an additional 2 h with CCK-8 reagent (100 μL/mL medium) and the absorbance is read at 450 nm using a microplate reader. Cell proliferation inhibition rates are calculated according to the following formula: the proliferation inhibition ratio (%)=1-[(A1-A4)/(A2-A3)]×100, where, A1 is the OD value of drug experimental group, A2 is the OD value of blank control group, A3 is the OD value of the RPMI1640 medium without cells, and A4 is the OD value of drugs with the same concentration as A1 but without cells. The IC50 value, which represents the concentration of the drug that demonstrates 50% of cell growth inhibition, is calculated by nonlinear regression analysis using GraphPad Prism software[1]. |
體外活性 | 方法: 人乳腺癌細(xì)胞 MCF-7 用 Tanshinone IIA (0.0625-1 μg/mL) 處理 5 天,使用 MTT assay 檢測(cè)細(xì)胞活力。 結(jié)果: Tanshinone IIA 對(duì)細(xì)胞生長(zhǎng)有劑量和時(shí)間依賴性的抑制作用,IC50 為 0.25 μg/mL,1 μg/mL 時(shí)最大抑制細(xì)胞生長(zhǎng) (>80%)。[1] 方法: 人乳腺癌細(xì)胞 MCF-7 用 Tanshinone IIA (5-20 μM) 處理 12-48 h,使使用 Flow cytometry 檢測(cè)細(xì)胞凋亡。 結(jié)果: 在 Tanshinone IIA 的存在下觀察到濃度依賴性的細(xì)胞凋亡誘導(dǎo)。[2] |
體內(nèi)活性 | 方法: 為檢測(cè)體內(nèi)抗腫瘤活性,將 Tanshinone IIA (30 mg/kg) 注射給攜帶 MCF-7 腫瘤異種移植物的 BALB/c-nu 裸鼠,每周五次,持續(xù)兩周。 結(jié)果: Tanshinone IIA 治療顯著減少了腫瘤的大小和重量。Tanshinone IIA 處理增強(qiáng)了體內(nèi) PARP 和 caspase-3 的切割。[2] |
存儲(chǔ)條件 | Powder: -20°C for 3 years | Shipping with blue ice. |
溶解度 | DMSO : 2.94 mg/mL (10 mM), The compound is unstable in solution. Please use soon. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 0.29 mg/mL (0.99 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. |
關(guān)鍵字 | inhibit | VEGFR | Vascular endothelial growth factor receptor | Tanshinone IIA | Inhibitor |
相關(guān)產(chǎn)品 | Ribociclib | Lenvatinib | Axitinib | Sorafenib tosylate | Lenvatinib mesylate | Sanguinarine chloride | Regorafenib | Pazopanib | Nintedanib | Sorafenib | Regorafenib monohydrate | Taxifolin |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.2651萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營(yíng)模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP1年
|
西安久啟生物科技有限公司
|
2024-12-27 | |
詢價(jià) |
VIP6年
|
湖北阡陌生物科技有限公司
|
2024-12-27 | |
詢價(jià) |
VIP1年
|
南京丙承生物科技有限公司
|
2024-12-27 | |
詢價(jià) |
VIP4年
|
河南沃咖斯生物科技有限公司
|
2024-12-27 | |
詢價(jià) |
VIP6年
|
湖北鴻福達(dá)生物科技有限公司
|
2024-12-27 | |
¥30000 |
VIP5年
|
武漢克米克生物醫(yī)藥技術(shù)有限公司
|
2024-12-27 | |
詢價(jià) |
VIP1年
|
銘龍(咸寧)醫(yī)藥有限公司
|
2024-12-27 | |
詢價(jià) |
VIP6年
|
陜西新天域生物科技有限公司
|
2024-12-27 | |
詢價(jià) |
VIP5年
|
眾鑫辰實(shí)(武漢)科技有限公司
|
2024-12-27 | |
¥400 |
VIP1年
|
陜西昊辰生物有限公司
|
2024-12-27 |